{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:16:31Z","timestamp":1788297391263,"version":"build-2803163510"},"reference-count":74,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bbadis.2025.167970","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T12:23:24Z","timestamp":1751545404000},"page":"167970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in clinical studies of peptide drugs in stroke disease"],"prefix":"10.1016","volume":"1871","author":[{"given":"Yan","family":"Huo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzhen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijie","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-6748","authenticated-orcid":false,"given":"Mingliang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbadis.2025.167970_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114768","article-title":"Ischemic stroke and infection: a brief update on mechanisms and potential therapies","volume":"193","author":"Ghelani","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bbadis.2025.167970_bb0010","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/17474930221080343","article-title":"Corrigendum to: World Stroke Organization (WSO): global stroke fact sheet 2022","volume":"17","year":"2022","journal-title":"Int. J. Stroke"},{"key":"10.1016\/j.bbadis.2025.167970_bb0015","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","article-title":"Heart disease and stroke statistics-2023 update: a report from the American Heart Association","volume":"147","author":"Tsao","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.bbadis.2025.167970_bb0020","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1097\/MOT.0000000000001015","article-title":"Mitochondria and ischemia reperfusion injury","volume":"27","author":"Panconesi","year":"2022","journal-title":"Curr. Opin. Organ Transplant."},{"key":"10.1016\/j.bbadis.2025.167970_bb0025","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11910-023-01282-2","article-title":"Neuroinflammation in acute ischemic and hemorrhagic stroke","volume":"23","author":"Alsbrook","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.bbadis.2025.167970_bb0030","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pneurobio.2013.11.006","article-title":"Excitotoxicity and stroke: identifying novel targets for neuroprotection","volume":"115","author":"Lai","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.bbadis.2025.167970_bb0035","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.2174\/1381612826666200708133912","article-title":"Pathophysiology of ischemic stroke: role of oxidative stress","volume":"26","author":"Orellana-Urzua","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bbadis.2025.167970_bb0040","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s12975-020-00806-z","article-title":"Cell death pathways in ischemic stroke and targeted pharmacotherapy","volume":"11","author":"Datta","year":"2020","journal-title":"Transl. Stroke Res."},{"key":"10.1016\/j.bbadis.2025.167970_bb0045","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/S0140-6736(12)60768-5","article-title":"The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial","volume":"379","author":"I.S.T.c. group","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2025.167970_bb0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.11138\/FNeur\/2018.33.1.005","article-title":"Mechanical thrombectomy for acute ischemic stroke: the therapeutic window is larger but still \u201ctime is brain\u201d","volume":"33","author":"Zivelonghi","year":"2018","journal-title":"Funct. Neurol."},{"key":"10.1016\/j.bbadis.2025.167970_bb0055","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1136\/jnnp-2020-324283","article-title":"The future of neuroprotection in stroke","volume":"92","author":"Chamorro","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.bbadis.2025.167970_bb0060","article-title":"Progress of peptide drugs research at home and abroad","volume":"07","author":"Zhu","year":"2008","journal-title":"Chin. Pharm."},{"key":"10.1016\/j.bbadis.2025.167970_bb0065","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1016\/j.bmc.2018.01.012","article-title":"Peptide chemistry toolbox - transforming natural peptides into peptide therapeutics","volume":"26","author":"Erak","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbadis.2025.167970_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2022.103464","article-title":"Peptide-based drug discovery: current status and recent advances","volume":"28","author":"Sharma","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbadis.2025.167970_bb0075","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(20)30258-0","article-title":"Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial","volume":"395","author":"Hill","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bbadis.2025.167970_bb0080","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.copbio.2006.10.002","article-title":"Therapeutic peptides: technological advances driving peptides into development","volume":"17","author":"Sato","year":"2006","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.bbadis.2025.167970_bb0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.sbi.2016.12.009","article-title":"Peptides and peptidomimetics as regulators of protein-protein interactions","volume":"44","author":"Cunningham","year":"2017","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.bbadis.2025.167970_bb0090","doi-asserted-by":"crossref","first-page":"8896","DOI":"10.1002\/anie.201412070","article-title":"Structure-based design of inhibitors of protein-protein interactions: mimicking peptide binding epitopes","volume":"54","author":"Pelay-Gimeno","year":"2015","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.bbadis.2025.167970_bb0095","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2012.10","article-title":"Features of protein-protein interactions that translate into potent inhibitors: topology, surface area and affinity","volume":"14","author":"Smith","year":"2012","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.bbadis.2025.167970_bb0100","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/mt.2015.214","article-title":"Modulation of protein-protein interactions for the development of novel therapeutics","volume":"24","author":"Petta","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bbadis.2025.167970_bb0105","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40262-013-0079-0","article-title":"Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides","volume":"52","author":"Diao","year":"2013","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bbadis.2025.167970_bb0110","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1211\/0022357011776522","article-title":"Transport studies of insulin across rat jejunum in the presence of chicken and duck ovomucoids","volume":"53","author":"Agarwal","year":"2001","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.bbadis.2025.167970_bb0115","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejpb.2013.12.017","article-title":"The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition","volume":"86","author":"Welling","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.bbadis.2025.167970_bb0120","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/187221109788452221","article-title":"Oral protein delivery: a patent review of academic and industrial approaches","volume":"3","author":"Werle","year":"2009","journal-title":"Recent Pat. Drug Deliv. Formul."},{"key":"10.1016\/j.bbadis.2025.167970_bb0125","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1039\/C4SC00045E","article-title":"Functionalised staple linkages for modulating the cellular activity of stapled peptides","volume":"5","author":"Lau","year":"2014","journal-title":"Chem. Sci."},{"key":"10.1016\/j.bbadis.2025.167970_bb0130","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1016\/j.apsb.2023.05.004","article-title":"Discovery of an orally effective double-stapled peptide for reducing ovariectomy-induced bone loss in mice","volume":"13","author":"Cong","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbadis.2025.167970_bb0135","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.drudis.2009.10.009","article-title":"Synthetic therapeutic peptides: science and market","volume":"15","author":"Vlieghe","year":"2010","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.bbadis.2025.167970_bb0140","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0167-7799(98)01186-X","article-title":"The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals","volume":"16","author":"Pettit","year":"1998","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.bbadis.2025.167970_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035187","article-title":"TumorHoPe: a database of tumor homing peptides","volume":"7","author":"Kapoor","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.bbadis.2025.167970_bb0150","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1158\/1078-0432.CCR-19-3258","article-title":"ANG1005, a brain-penetrating peptide-drug conjugate, shows activity in patients with breast cancer with leptomeningeal carcinomatosis and recurrent brain metastases","volume":"26","author":"Kumthekar","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbadis.2025.167970_bb0155","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1039\/C6CS00076B","article-title":"Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery","volume":"45","author":"Oller-Salvia","year":"2016","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.bbadis.2025.167970_bb0160","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/S0196-9781(97)00242-8","article-title":"Bioavailability and transport of peptides and peptide drugs into the brain","volume":"18","author":"Egleton","year":"1997","journal-title":"Peptides"},{"key":"10.1016\/j.bbadis.2025.167970_bb0165","doi-asserted-by":"crossref","first-page":"5871","DOI":"10.1073\/pnas.80.19.5871","article-title":"Bis-penicillamine enkephalins possess highly improved specificity toward delta opioid receptors","volume":"80","author":"Mosberg","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbadis.2025.167970_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21207609","article-title":"Pathophysiology and treatment of stroke: present status and future perspectives","volume":"21","author":"Kuriakose","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2025.167970_bb0175","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s12028-021-01287-0","article-title":"CN-105 in participants with acute supratentorial intracerebral hemorrhage (CATCH) trial","volume":"36","author":"James","year":"2022","journal-title":"Neurocrit. Care."},{"key":"10.1016\/j.bbadis.2025.167970_bb0180","series-title":"A Phase 1 Study to Evaluate Safety and Tolerability of NoNO-42 in Healthy Adults, (ClinicalTrials.gov, NCT05636306)","author":"N. Inc","year":"2024"},{"key":"10.1016\/j.bbadis.2025.167970_bb0185","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s40265-024-02121-5","article-title":"Efficacy and safety of sovateltide in patients with acute cerebral ischaemic stroke: a randomised, double-blind, placebo-controlled, multicentre, phase III clinical trial","volume":"84","author":"Gulati","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.bbadis.2025.167970_bb0190","doi-asserted-by":"crossref","first-page":"61","DOI":"10.17116\/jnevro20181183261-68","article-title":"The efficacy of semax in the tretament of patients at different stages of ischemic stroke","volume":"118","author":"Gusev","year":"2018","journal-title":"Zh. Nevrol. Psikhiatr. Im. S S Korsakova"},{"key":"10.1016\/j.bbadis.2025.167970_bb0195","unstructured":"A. Therapeutics, https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12623001110673, in: ACTRN12623001110673, ANZCTR."},{"key":"10.1016\/j.bbadis.2025.167970_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102901","article-title":"Efficacy and safety of adrenomedullin for acute ischemic stroke (AMFIS): a phase 2, randomized, double-blinded, placebo-controlled, clinical trial","volume":"77","author":"Yoshimoto","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.bbadis.2025.167970_bb0205","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.2147\/DDDT.S460831","article-title":"Intravenous odatroltide for acute ischemic stroke within 24 hours of onset: a phase 2, multicenter, randomized, double-blind, placebo-controlled study","volume":"18","author":"Chao","year":"2024","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.bbadis.2025.167970_bb0210","doi-asserted-by":"crossref","DOI":"10.3390\/ph14121297","article-title":"Safety of cerebrolysin for neurorecovery after acute ischemic stroke: a systematic review and meta-analysis of twelve randomized-controlled trials","volume":"14","author":"Strilciuc","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.bbadis.2025.167970_bb0215","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s00018-022-04257-7","article-title":"Novel contact-kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic stroke","volume":"79","author":"Zhang","year":"2022","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bbadis.2025.167970_bb0220","doi-asserted-by":"crossref","DOI":"10.1038\/srep34834","article-title":"Neuroprotective pentapeptide CN-105 improves functional and histological outcomes in a murine model of intracerebral hemorrhage","volume":"6","author":"Lei","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbadis.2025.167970_bb0225","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/acn3.399","article-title":"Apolipoprotein E mimetic peptide, CN-105, improves outcomes in ischemic stroke","volume":"4","author":"Tu","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.bbadis.2025.167970_bb0230","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1126\/science.1072873","article-title":"Treatment of ischemic brain damage by perturbing NMDA receptor- PSD-95 protein interactions","volume":"298","author":"Aarts","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.bbadis.2025.167970_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb1498","article-title":"Plasmin-resistant PSD-95 inhibitors resolve effect-modifying drug-drug interactions between alteplase and nerinetide in acute stroke","volume":"13","author":"Mayor-Nunez","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbadis.2025.167970_bb0240","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.bbadis.2025.167970_bb0245","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/3-540-32967-6_9","article-title":"Endothelin","author":"Davenport","year":"2006","journal-title":"Handb. Exp. Pharmacol."},{"key":"10.1016\/j.bbadis.2025.167970_bb0250","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.33549\/physiolres.933859","article-title":"A novel neuroregenerative approach using ET(B) receptor agonist, IRL-1620, to treat CNS disorders","volume":"67","author":"Gulati","year":"2018","journal-title":"Physiol. Res."},{"key":"10.1016\/j.bbadis.2025.167970_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063146","article-title":"Sovateltide mediated endothelin B receptors agonism and curbing neurological disorders","volume":"23","author":"Ranjan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2025.167970_bb0260","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40263-020-00783-9","article-title":"Safety and efficacy of sovateltide (IRL-1620) in a multicenter randomized controlled clinical trial in patients with acute cerebral ischemic stroke","volume":"35","author":"Gulati","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.bbadis.2025.167970_bb0265","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s40265-023-01922-4","article-title":"Sovateltide: first approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.bbadis.2025.167970_bb0270","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s10571-009-9432-0","article-title":"Semax and Pro-Gly-Pro activate the transcription of neurotrophins and their receptor genes after cerebral ischemia","volume":"30","author":"Dmitrieva","year":"2010","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.bbadis.2025.167970_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126179","article-title":"Brain protein expression profile confirms the protective effect of the ACTH((4-7))PGP peptide (Semax) in a rat model of cerebral ischemia-reperfusion","volume":"22","author":"Sudarkina","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbadis.2025.167970_bb0280","unstructured":"https:\/\/argenica.com.au\/the-science\/, in, Argenica Therapeutics."},{"key":"10.1016\/j.bbadis.2025.167970_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25132977","article-title":"Poly-arginine-18 (R18) confers neuroprotection through glutamate receptor modulation, intracellular calcium reduction, and preservation of mitochondrial function","volume":"25","author":"MacDougall","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bbadis.2025.167970_bb0290","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s10989-018-09799-8","article-title":"Poly-arginine peptide R18D reduces neuroinflammation and functional deficits following traumatic brain injury in the Long-Evans rat","volume":"25","author":"Chiu","year":"2019","journal-title":"Int. J. Pept. Res. Ther."},{"key":"10.1016\/j.bbadis.2025.167970_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.curtheres.2020.100584","article-title":"Effect of polyarginine peptide R18D following a traumatic brain injury in Sprague-Dawley rats","volume":"92","author":"Chiu","year":"2020","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"10.1016\/j.bbadis.2025.167970_bb0300","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2021.759729","article-title":"Arginine and arginine-rich peptides as modulators of protein aggregation and cytotoxicity associated with Alzheimer\u2019s disease","volume":"14","author":"Mamsa","year":"2021","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.bbadis.2025.167970_bb0305","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13041-018-0352-0","article-title":"Poly-arginine R18 and R18D (D-enantiomer) peptides reduce infarct volume and improves behavioural outcomes following perinatal hypoxic-ischaemic encephalopathy in the P7 rat","volume":"11","author":"Edwards","year":"2018","journal-title":"Mol. Brain"},{"key":"10.1016\/j.bbadis.2025.167970_bb0310","author":"A. Therapeutics"},{"key":"10.1016\/j.bbadis.2025.167970_bb0315","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1006\/bbrc.1993.1451","article-title":"Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma","volume":"192","author":"Kitamura","year":"1993","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbadis.2025.167970_bb0320","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.expneurol.2005.10.027","article-title":"Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis","volume":"197","author":"Xia","year":"2006","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bbadis.2025.167970_bb0325","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3892\/or.2015.4011","article-title":"Hypoxia-induced apoptosis is blocked by adrenomedullin via upregulation of Bcl-2 in human osteosarcoma cells","volume":"34","author":"Wu","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbadis.2025.167970_bb0330","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.562","article-title":"Interleukin-1beta promotes hypoxia-induced apoptosis of glioblastoma cells by inhibiting hypoxia-inducible factor-1 mediated adrenomedullin production","volume":"5","author":"Sun","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bbadis.2025.167970_bb0335","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.bbagen.2009.03.012","article-title":"Circulating hormone adrenomedullin and its binding protein protect neural cells from hypoxia-induced apoptosis","volume":"1790","author":"Wang","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bbadis.2025.167970_bb0340","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1210\/en.2002-220233","article-title":"Adrenomedullin inhibits doxorubicin-induced cultured rat cardiac myocyte apoptosis via a cAMP-dependent mechanism","volume":"143","author":"Tokudome","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.bbadis.2025.167970_bb0345","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/7201549","article-title":"Protective effect of adrenomedullin on rat Leydig cells from lipopolysaccharide-induced inflammation and apoptosis via the PI3K\/Akt signaling pathway ADM on rat Leydig cells from inflammation and apoptosis","volume":"2016","author":"Zhou","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.bbadis.2025.167970_bb0350","unstructured":"CTR20202357 detailed information., in: http:\/\/www.chinadrugtrials.org.cn\/clinicaltrials.searchlistdetail.dhtml?id=8b1e3cfc9e3a446daa2f90c5bad4f855, Chinese Clinical Trials Registry, 2020."},{"key":"10.1016\/j.bbadis.2025.167970_bb0355","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neuroscience.2025.01.040","article-title":"The possible role of cerebrolysin in the management of vascular dementia: leveraging concepts","volume":"568","author":"Al-Kuraishy","year":"2025","journal-title":"Neuroscience"},{"key":"10.1016\/j.bbadis.2025.167970_bb0360","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1080\/14737175.2018.1500459","article-title":"Cerebrolysin: a multi-target drug for recovery after stroke","volume":"18","author":"Brainin","year":"2018","journal-title":"Expert. Rev. Neurother."},{"key":"10.1016\/j.bbadis.2025.167970_bb0365","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1161\/STROKEAHA.111.000831","article-title":"Sonic hedgehog signaling pathway mediates cerebrolysin-improved neurological function after stroke","volume":"44","author":"Zhang","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.bbadis.2025.167970_bb0370","article-title":"Cerebrolysin for acute ischaemic stroke","volume":"10","author":"Ziganshina","year":"2023","journal-title":"Cochrane Database Syst. Rev."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443925003187?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925443925003187?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:46:20Z","timestamp":1788295580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925443925003187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":74,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0925443925003187"],"URL":"https:\/\/doi.org\/10.1016\/j.bbadis.2025.167970","relation":{},"ISSN":["0925-4439"],"issn-type":[{"value":"0925-4439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in clinical studies of peptide drugs in stroke disease","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbadis.2025.167970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"167970"}}